How to buy Sinovac Biotech Ltd shares in Ireland | $6.47

Sinovac Biotech Ltd is a biotechnology business based in the US. Sinovac Biotech Ltd shares (SVA) are listed on the NASDAQ and all prices are listed in US Dollars. Sinovac Biotech Ltd employs 910 staff and has a trailing 12-month revenue of around USD$224.9 million.

Sponsored For

Beginners Choice

DEGIRO

Sponsored For

Low-cost Trading

eToro

Sponsored For

Overall Broker

Plus500

How to buy shares in Sinovac Biotech Ltd from Ireland

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sinovac Biotech Ltd Find the stock by name or ticker symbol: SVA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sinovac Biotech Ltd reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$6.47, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sinovac Biotech Ltd, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sinovac Biotech Ltd. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare online brokers to trade stocks, ETFs and CFDs

Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89 % of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Sort by:

Name	Product	Number of Stocks	CFDs	Shares	Available Markets	Link
DEGIRO		Access to global markets	No	Yes	AU, AT, BE, CA, CH, CZ, DE, DK, ES, FR, FI, GR, HK, HU, IT, JP, NO, PT, PL, IE, SG, SE, TR, UK, US	Go to site More Info	Your capital is at risk.		loading Fetching your data...
eToro		2,000+	Yes	Yes	Worldwide with exception.	Go to site 71% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...
Plus500		2,000+	Yes	Yes	US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK	Go to site 76.4% of CFD accounts lose money More Info	CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Sinovac Biotech Ltd share price

Is it a good time to buy Sinovac Biotech Ltd stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Sinovac Biotech Ltd under- or over-valued?

Valuing Sinovac Biotech Ltd stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sinovac Biotech Ltd's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sinovac Biotech Ltd's P/E ratio

Sinovac Biotech Ltd's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Sinovac Biotech Ltd shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sinovac Biotech Ltd's EBITDA

Sinovac Biotech Ltd's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$59.4 million.

The EBITDA is a measure of a Sinovac Biotech Ltd's overall financial performance and is widely used to measure a its profitability.

Shorting Sinovac Biotech Ltd shares

There are currently 199,773 Sinovac Biotech Ltd shares held short by investors – that's known as Sinovac Biotech Ltd's "short interest". This figure is 0.1% down from 199,973 last month.

There are a few different ways that this level of interest in shorting Sinovac Biotech Ltd shares can be evaluated.

Sinovac Biotech Ltd's "short interest ratio" (SIR)

Sinovac Biotech Ltd's "short interest ratio" (SIR) is the quantity of Sinovac Biotech Ltd shares currently shorted divided by the average quantity of Sinovac Biotech Ltd shares traded daily (recently around inf billion). Sinovac Biotech Ltd's SIR currently stands at 0. In other words for every 100,000 Sinovac Biotech Ltd shares traded daily on the market, roughly 0 shares are currently held short.

However Sinovac Biotech Ltd's short interest can also be evaluated against the total number of Sinovac Biotech Ltd shares, or, against the total number of tradable Sinovac Biotech Ltd shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sinovac Biotech Ltd's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sinovac Biotech Ltd shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable Sinovac Biotech Ltd shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sinovac Biotech Ltd.

Frequently asked questions

• What percentage of Sinovac Biotech Ltd is owned by insiders or institutions?

  Currently 15.887% of Sinovac Biotech Ltd shares are held by insiders and 23.11% by institutions.

• How many people work for Sinovac Biotech Ltd?

  Latest data suggests 910 work at Sinovac Biotech Ltd.

• When does the fiscal year end for Sinovac Biotech Ltd?

  Sinovac Biotech Ltd's fiscal year ends in December.

• Where is Sinovac Biotech Ltd based?

  Sinovac Biotech Ltd's address is: No.39, SHANGDI West Road, Beijing, China, 100085

• What is Sinovac Biotech Ltd's ISIN number?

  Sinovac Biotech Ltd's international securities identification number is: AGP8696W1045

• What is Sinovac Biotech Ltd's CUSIP number?

  Sinovac Biotech Ltd's Committee on Uniform Securities Identification Procedures number is: P8696W104